Position in ACET
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,689,240
+$1,301,163 QoQ
Shares Held
195,514
+552.9% QoQ
Ownership
2.09%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#10
of 56 holders
Holding Since
Jun 2023
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ACET Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Schonfeld Strategic Advisors LLC holds $420,669,608 across 133 Biotechnology names. ACET ranks #59 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INBX |
Inhibrx Biosciences, Inc.
|
697,586 | $66,096,273 | |
| 2 | AGIO |
Agios Pharmaceuticals, Inc.
|
520,083 | $19,300,280 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
77,272 | $18,620,233 | |
| 4 | VRDN |
Viridian Therapeutics, Inc.\DE
|
793,508 | $14,576,741 | |
| 5 | MBX |
MBX Biosciences, Inc.
|
248,670 | $13,726,584 | |
| 6 | XENE |
Xenon Pharmaceuticals Inc.
|
227,330 | $13,721,638 | |
| 7 | PTCT |
Ptc Therapeutics, Inc.
|
147,425 | $12,025,457 | |
| 8 | INSM |
INSMED Inc
|
104,378 | $11,128,782 |
All Filings in ACET
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,689,240 | 195,514 | Shares | Sole | 2026-08-14 | |
| 2025-09-30 | $388,077 | 479,108 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,146,857 | 1,880,095 | Shares | Sole | 2025-08-14 | |
| 2024-06-30 | $35,816 | 29,600 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $2,665,840 | 1,134,400 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $378,189 | 200,100 | Shares | Sole | 2024-02-14 | |
| 2023-06-30 | $42,039 | 17,300 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||